CIRB #H-33418\/ CTSU #A151216 (ALCHEMIST)<\/strong>:<\/a> Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)<\/p>\n CIRB #H-40717\/ CTSU #A081801 (ACCIO)<\/strong>:<\/a> Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO) <\/span><\/p>\n WCG IRB #H-43210\/ Merck #MK-7684A-006 (KEYVIBE-006):<\/strong><\/a> Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK- 7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC<\/p>\n BMC IRB #H-43785\/ LCMC LEADER: Neoadjuvant Screening Trial:<\/strong><\/a>\u00a0L<\/strong>CMC4 E<\/strong>valuation of A<\/strong>ctionable D<\/strong>rivers in E<\/strong>arly Stage Lung Cancer<\/strong>s<\/p>\n WCG IRB #H-43834\/ Genentech #ML41591 (NAUTIKA1):<\/strong><\/a> Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer<\/p>\n WCG IRB #H-43631 \/ GSK #213824 (GALAXIES LUNG-201)<\/strong>:<\/a> A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced\/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer<\/p>\n CIRB #H-44518\/ SWOG #S2302 (PRAGMATICA-LUNG):<\/strong><\/a> A Prospective Randomized Study of Ramucirumab Plus Pembrolizumab Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer<\/p>\n WCG IRB #H-44076\/ Janssen #61186372NSC2002 (PALOMA-2):<\/strong><\/a> A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer<\/p>\n Advarra IRB #H-44434\/ Eli Lilly #J3M-MC-JZQB (SUNRAY-01):<\/strong><\/a> A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression \u226550% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression<\/p>\n Central IRB #H-44990\/ SeaGen #SGNB6A-002:<\/strong><\/a> A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (pending)<\/b><\/p>\n CIRB #H-40325\/ SWOG #S1827 (MAVERICK):<\/strong><\/a> MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation: A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)<\/p>\n CIRB #H-41197\/ NRG #LU007 (RAPTOR):<\/strong><\/a> RA<\/strong>ndomized P<\/strong>hase II\/III T<\/strong>rial O<\/strong>f Consolidation R<\/strong>adiation + Immunotherapy for ES-SCLC: RAPTOR trial<\/p>\n CIRB #H-42287\/ NRG #CC009:<\/strong><\/a> Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer (pending)<\/b><\/p>\nALCHEMIST Sub-study:<\/h5>\n
Metastatic Stage IV Trials:<\/h4>\n
Small Cell Lung Cancer (SCLC):<\/h3>\n
Esophageal\/Stomach:<\/h3>\n